IL285416A - Antibodies for cancer treatment - Google Patents

Antibodies for cancer treatment

Info

Publication number
IL285416A
IL285416A IL285416A IL28541621A IL285416A IL 285416 A IL285416 A IL 285416A IL 285416 A IL285416 A IL 285416A IL 28541621 A IL28541621 A IL 28541621A IL 285416 A IL285416 A IL 285416A
Authority
IL
Israel
Prior art keywords
antibody
cells
cancer
fragment
trem2
Prior art date
Application number
IL285416A
Other languages
English (en)
Hebrew (he)
Inventor
Amit Ido
Bornstein-Ovits Chamutal
Yalin Adam
MOSHE Adi
BARBOY Oren
Weiner Assaf
KATZENELENBOGEN Yonatan
Jaitin Diego
SHEBAN Fadi
Original Assignee
Yeda Res & Dev
Amit Ido
Chamutal Bornstein Ovits
Yalin Adam
MOSHE Adi
BARBOY Oren
Weiner Assaf
KATZENELENBOGEN Yonatan
Jaitin Diego
SHEBAN Fadi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Amit Ido, Chamutal Bornstein Ovits, Yalin Adam, MOSHE Adi, BARBOY Oren, Weiner Assaf, KATZENELENBOGEN Yonatan, Jaitin Diego, SHEBAN Fadi filed Critical Yeda Res & Dev
Priority to IL285416A priority Critical patent/IL285416A/en
Priority to CN202280065311.9A priority patent/CN118076643A/zh
Priority to CA3226996A priority patent/CA3226996A1/en
Priority to IL310605A priority patent/IL310605A/en
Priority to EP22757699.8A priority patent/EP4380975A1/en
Priority to PCT/IL2022/050849 priority patent/WO2023012802A1/en
Priority to JP2024506734A priority patent/JP2024532705A/ja
Publication of IL285416A publication Critical patent/IL285416A/en
Priority to US18/432,214 priority patent/US20240239886A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL285416A 2021-08-05 2021-08-05 Antibodies for cancer treatment IL285416A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL285416A IL285416A (en) 2021-08-05 2021-08-05 Antibodies for cancer treatment
CN202280065311.9A CN118076643A (zh) 2021-08-05 2022-08-04 治疗癌症的抗体
CA3226996A CA3226996A1 (en) 2021-08-05 2022-08-04 Antibodies for treating cancer
IL310605A IL310605A (en) 2021-08-05 2022-08-04 Antibodies for treating cancer
EP22757699.8A EP4380975A1 (en) 2021-08-05 2022-08-04 Antibodies for treating cancer
PCT/IL2022/050849 WO2023012802A1 (en) 2021-08-05 2022-08-04 Antibodies for treating cancer
JP2024506734A JP2024532705A (ja) 2021-08-05 2022-08-04 癌を治療するための抗体
US18/432,214 US20240239886A1 (en) 2021-08-05 2024-02-05 Antibodies for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL285416A IL285416A (en) 2021-08-05 2021-08-05 Antibodies for cancer treatment

Publications (1)

Publication Number Publication Date
IL285416A true IL285416A (en) 2023-03-01

Family

ID=83004541

Family Applications (2)

Application Number Title Priority Date Filing Date
IL285416A IL285416A (en) 2021-08-05 2021-08-05 Antibodies for cancer treatment
IL310605A IL310605A (en) 2021-08-05 2022-08-04 Antibodies for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL310605A IL310605A (en) 2021-08-05 2022-08-04 Antibodies for treating cancer

Country Status (7)

Country Link
US (1) US20240239886A1 (https=)
EP (1) EP4380975A1 (https=)
JP (1) JP2024532705A (https=)
CN (1) CN118076643A (https=)
CA (1) CA3226996A1 (https=)
IL (2) IL285416A (https=)
WO (1) WO2023012802A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AR133688A1 (es) * 2023-08-30 2025-10-22 Teijin Pharma Ltd Agente terapéutico para enfermedades neurodegenerativas
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
US20180043014A1 (en) * 2008-08-20 2018-02-15 Celldex Therapeutics, Inc. Compositions Using Antibodies Directed to GPNMB and Uses Thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180043014A1 (en) * 2008-08-20 2018-02-15 Celldex Therapeutics, Inc. Compositions Using Antibodies Directed to GPNMB and Uses Thereof
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMON, PAULINE, ET AL., CHARACTERIZATION OF MOLECULAR AND SPATIAL DIVERSITY OF MACROPHAGES IN HEPATOCELLULAR CARCINOMA., 1 July 2021 (2021-07-01) *
KATZENELENBOGEN, YONATAN, ET AL., COUPLED SCRNA-SEQ AND INTRACELLULAR PROTEIN ACTIVITY REVEAL AN IMMUNOSUPPRESSIVE ROLE OF TREM2 IN CANCER., 20 August 2020 (2020-08-20) *

Also Published As

Publication number Publication date
IL310605A (en) 2024-04-01
EP4380975A1 (en) 2024-06-12
CN118076643A (zh) 2024-05-24
JP2024532705A (ja) 2024-09-10
WO2023012802A1 (en) 2023-02-09
CA3226996A1 (en) 2023-02-09
US20240239886A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
US20240239886A1 (en) Antibodies for treating cancer
JP7124257B2 (ja) 抗ｐｄ‐ｌ１抗体およびその使用
JP7206193B2 (ja) 抗ｃｄ７３抗体およびその使用
CN108350082B (zh) Pd-l1抗体及其用途
JP2023516388A (ja) 抗ｃｃｒ８剤
AU2018274932B2 (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
KR20220024211A (ko) 항-cd47 항체 및 그것의 사용
CN119735678B (zh) 肿瘤抗原依赖性cd40激动剂单域抗体
EP4426740A2 (en) Novel anti-lilrb2 antibodies and derivative products
CN115611984A (zh) NKp46抗体及其制备方法和应用
US20220372145A1 (en) Methods of treating cancer
RU2826236C1 (ru) Антитело против vsig4 или его антигенсвязывающий фрагмент и их применение
KR20260004605A (ko) 길항성 항-cd40 인간화 항체
HK40025067A (en) Anti-pd-l1 antibodies and uses thereof
HK40062727A (en) Pd-l1 antibodies and uses thereof
CN121779558A (zh) Sema3g抗原结合蛋白及其用途
HK40005495A (en) Anti-cd73 antibodies and uses thereof
HK40005495B (en) Anti-cd73 antibodies and uses thereof